Skip to content
Medical Health Aged Care

QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

QPS Holdings, LLC 3 mins read
NEWARK, Del.--BUSINESS WIRE--

QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.

The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.

The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.

“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.

The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.

“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.


Contact details:

Gabrielle Pastore
1-302-635-4290
Gabrielle.Pastore@qps.com

Media

More from this category

  • Medical Health Aged Care
  • 23/10/2024
  • 14:43
Dementia Australia

Dementia Australia supports Bridgetown & Nannup

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Bridgetown and Nannup between 6 and 8 November. It is estimated there are more than 40,500 people living with all forms of dementia in Western Australia. Without a medical breakthrough this number is expected to increase to almost 87,000 people living with dementia by 2054. These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia…

  • Contains:
  • COVID19, Medical Health Aged Care
  • 23/10/2024
  • 08:55
PSS Distributors

Failed Vaccines Put Thousands of Aussie Lives at Risk and Cost the Government $22 Million in Wastage

The eye-watering cost of vaccine wastage and the serious public health threat posed by compromised vaccines already given to Australians are making headlines across major news outlets right now, underscoring the need for urgent action. The national press reported last week that over 1,200 patients at a general practice in Sydney’s inner west – including hundreds of children receiving their first vaccinations under the age of five –were informed that the vaccines they received between December 2019 and July 2024 may not be fully effective due to improper storage, leaving them prone to serious diseases like polio, hepatitis, meals, whooping…

  • Medical Health Aged Care, Political
  • 23/10/2024
  • 06:45
Public Health Association of Australia / Royal Australasian College of Physicians (RACP) /

Action on Australian Centre for Disease Control now more urgent than ever: health experts

23 October 2024: Leading Australian health experts have joined together today to call for the Government to urgently commit funds to establish a permanent Australian Centre for Disease Control (Australian CDC), saying that the Government’s election promise to create the organisation is now more pressing than ever. The call comes in the lead-up to the revised deadline for the delivery of the COVID-19 Inquiry Response Report (now due October 25), which the Government has said will help determine the Australian CDC’s future structure and function. It also comes in the wake of the retirement of the Interim CDC’s Head, Professor…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.